Geron Corp (GERN)

Mar 31, 2025, 4:32 PM EDT - 2 days ago

Geron Corp.: A Compelling Potential Buying Opportunity Thanks To Bearish Comments

Mar 31, 2025, 4:30 PM EDT - 2 days ago

Geron Plans to Announce First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 2:34 PM EDT - 2 days ago

Biotech Stocks Q1 2025 Recap: Winners And Underperformers

CMRX CRVO CVS LLY NVO SEPN

Mar 28, 2025, 10:18 AM EDT - 5 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron

Mar 22, 2025, 12:31 PM EDT - 11 days ago

Lifshitz Law PLLC Announces Investigations of Geron Corporation (NASDAQ: GERN), and The Bancorp, Inc. (NASDAQ: TBBK)

TBBK

Mar 19, 2025, 4:30 PM EDT - 14 days ago

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 17, 2025, 5:19 PM EDT - 16 days ago

Geron Corp: How Concerned Should We Be About Rytelo Sales?

Mar 17, 2025, 7:42 AM EDT - 16 days ago

GERN Investors Have Opportunity to Lead the Geron Corporation Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - GERN

Mar 14, 2025, 3:04 PM EDT - 19 days ago

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Geron Corporation (GERN)

Mar 11, 2025, 4:30 PM EDT - 22 days ago

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

Mar 11, 2025, 4:02 PM EDT - 22 days ago

Geron Corporation Announces Departure of Chief Executive Officer

Feb 26, 2025, 12:12 PM EST - 5 weeks ago

Geron: Rytelo's Market Share Concerns Justified As 3L Dominates Early Sales

Feb 26, 2025, 11:31 AM EST - 5 weeks ago

Geron Corporation (GERN) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:30 AM EST - 5 weeks ago

Geron Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights

Feb 21, 2025, 4:21 PM EST - 5 weeks ago

3 Biotech/Healthcare Names Under $10 I Am Buying Now

ARDX MRNA PSNL TEM

Feb 21, 2025, 9:00 AM EST - 5 weeks ago

Geron to Participate at Upcoming Investor Conferences in March 2025

Feb 3, 2025, 10:46 AM EST - 2 months ago

Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

Feb 3, 2025, 9:00 AM EST - 2 months ago

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Jan 16, 2025, 1:46 PM EST - 2 months ago

Geron: Positive IMpactMF Trial Could Possibly Lead To Doubling Of RYTELO Sales

Dec 13, 2024, 6:36 AM EST - 3 months ago

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Dec 10, 2024, 9:00 AM EST - 4 months ago

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Dec 10, 2024, 9:00 AM EST - 4 months ago

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Nov 27, 2024, 9:00 AM EST - 4 months ago

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Nov 21, 2024, 3:05 PM EST - 4 months ago

Geron: A Strong Launch And Financial Deals Make It Attractive

Nov 11, 2024, 4:30 PM EST - 5 months ago

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development